RED BLOOD CELLS iStock-860621344-min.jpg

Invest Now
Change the Prognosis for Patients with Deadly Brain Cancers

RED BLOOD CELLS iStock-860621344-min.jpg

Consider making an investment today that may change the future of Glioblastoma patients.

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

RED BLOOD CELLS iStock-860621344-min.jpg

We’re raising money for critical research.

The prognosis for brain cancer is unacceptable – we’re working hard to change it.

Invisible Dots for Treatment Transportation

These “invisible dots” are scintillating nanoparticles – microscopic particles that are activated by ultra-low doses of x-ray radiation energy. This approach represents a novel drug treatment delivery vehicle. When sufficient quantity of the dots accumulate at the brain tumor, we can apply a small dose of radiation as a means of remote-controlled release of whatever treatment the dots have delivered to the tumor. In this way, the drug has a reduced risk of affecting neighboring, healthy tissues and is activated only once it hits its target. 

 

We have an anti-cancer drug currently in pre-clinical trials with the collaboration support of our partner, the world-renowned Barrow Neurological Institute. This cancer inhibitor has recently shown that it can effectively halt uncontrolled cancer cell division (growth) without killing the cells. These results suggest that the anti-cancer drug we are developing may be effective as a cancer treatment if delivered at a concentration that is great enough to be effective yet non-toxic to neighboring tissues. 

Recent Lab Results

Have a look at these two images. Both are microscopic images of human glioblastoma (brain cancer) cells grown in lab culture medium. The image on the left shows the cancer cells dividing uncontrollably, and rapidly, as cancer cells do. In contrast, the image on the right shows a batch of the same cell culture but it’s been exposed to our anti-cancer drug at a 1 µM dose.

image5.png
image6.png
RED BLOOD CELLS iStock-860621344-min.jpg

We’ve made progress – but our work here isn’t done.

“Working with world-class neurosurgeons and researchers is making a difference.”  ~John Clark, CEO

Tracking the Dots

Crossing the blood-brain barrier is one of the many hurdles in the treatment of glioblastoma (aka brain cancer). It’s no wonder the prognosis is so poor – this deadly and aggressive brain cancer is incredibly challenging to treat. Binding the dots (nanoparticles) with anti-cancer inhibitors is one part of the research we’re working on in the development of novel drug delivery vehicles. The other part is tracking the progress of the anti-cancer treatment once it’s been delivered by the dots. Here’s where Baylor, Scott & White comes into play. This Texas hospital has state and national recognition for its efforts in innovation, commitment to excellence, and quality healthcare. We are proud to be working with some of their finest physicians and clinical researchers. They have identified a series of brain cancer biomarkers which can be assayed to test if our anti-cancer drug has been delivered – and if it’s done its job of thwarting the growth of the tumorour cancer cells.

RED BLOOD CELLS iStock-860621344-min.jpg

Research is expensive – and it takes time.

RED BLOOD CELLS iStock-860621344-min.jpg

Consider making an investment today that may change the future of Glioblastoma patients.

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.